Deutsche Bank AG reiterated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note released on Thursday. Deutsche Bank AG currently has a GBX 5,600 ($74.28) price objective on the biopharmaceutical company’s stock.

AZN has been the subject of a number of other reports. Liberum Capital reaffirmed a buy rating and set a GBX 4,800 ($63.67) price objective on shares of AstraZeneca plc in a research note on Tuesday, September 5th. Morgan Stanley reaffirmed an overweight rating and set a GBX 5,600 ($74.28) price objective on shares of AstraZeneca plc in a research note on Friday, June 23rd. UBS AG set a GBX 4,550 ($60.35) price objective on AstraZeneca plc and gave the stock a neutral rating in a research note on Thursday, August 31st. Jefferies Group LLC lifted their price objective on AstraZeneca plc from GBX 4,350 ($57.70) to GBX 4,800 ($63.67) and gave the stock a hold rating in a research note on Monday, September 11th. Finally, Shore Capital reaffirmed a hold rating on shares of AstraZeneca plc in a research note on Tuesday, August 29th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the stock. AstraZeneca plc has a consensus rating of Hold and a consensus target price of GBX 5,111.27 ($67.80).

AstraZeneca plc (AZN) traded up 1.04% during trading on Thursday, hitting GBX 5154.00. The company had a trading volume of 1,573,396 shares. The company’s market capitalization is GBX 65.25 billion. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The firm has a 50-day moving average of GBX 4,738.46 and a 200 day moving average of GBX 4,897.65.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/06/astrazeneca-plc-azn-receives-buy-rating-from-deutsche-bank-ag.html.

The business also recently announced a dividend, which was paid on Monday, September 11th. Investors of record on Thursday, August 10th were issued a dividend of GBX 68.90 ($0.91) per share. The ex-dividend date was Thursday, August 10th. This represents a yield of 1.35%.

In related news, insider Nazneen Rahman bought 39 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The shares were acquired at an average price of GBX 4,370 ($57.97) per share, for a total transaction of £1,704.30 ($2,260.64).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.